Contrave Advisory Committee Date May Give Orexigen Late-Mover Advantage

Earlier panel critiques of Contrave rivals should provide insight on how FDA is weighing risk versus benefit in obesity space.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet